紫杉醇联合顺铂/卡铂方案治疗蒽环类耐药晚期乳腺癌40例临床分析

目的观察紫杉醇联合顺铂或卡铂方案对蒽环类耐药的晚期乳腺癌患者的临床疗效及毒副作用。方法 40例蒽环类耐药的晚期乳腺癌患者采用紫杉醇175mg/m2静滴第1日,顺铂30mg/m2静滴,第1～3日(或卡铂30mg/m2静点,第1日),28d为1个周期,2个周期后评价疗效,有效者至少化疗4个周期。结果 40例中完全缓解8例,部分缓解15例,稳定8例,进展9例,总有效率为57.5%(23/40)。主要毒性反应为恶心、呕吐,骨髓抑制。结论紫杉醇联合顺铂(或卡铂)方案治疗蒽环类耐药的晚期乳腺癌较好,不良反应可耐受。

Paclitilaxel Combined with Cisplatin/Kappa for Anthracycline Resistant Advanced Breast Cancer: A Clinical Analysis of 40 Cases

Objective To observe the curative effect and safety of combination chemotherapy of paclitaxewith cisplatin or Kappa for anthracycline resistant advanced breast cancer. Methods Forty cases,due to anthracycline chemotherapy resistance in advanced breast cancer,were given 175mg/m2 paclitaxel IV ld,cisplatin 30mg/m2 IV 1 - 3d（or 30mg/m2 Kappa IV ld）,with 28 days as one cycle,evaluation of the curative efficacy after 2 cycles and if response at least four cycles necessary. Results In 40 eases, 8 cases showed complete response （PR）, 15 part response （PR）, and 8 cases showed stability and 9 progress, the total efficient rate being 57.5%（23/40）, and the main toxic reactions included nausea and vomiting and myelosuppression. Conclusion Paclitilaxel（Tax） combined with DDP/Kappa is efficient in the treatment of anthracycline resistant advanced breast cancer,with tolerant adverse reactions.